Who will be the big winner in the first imitation snatch battle in 2022?

[Pharmaceutical Network Industry News] In recent years, the approval of the first generic drugs has been accelerated in Chin.
The data shows that from 2019 to 2021, the number of approved varieties of the first generic drugs in China has increased from 53 to more than 78, a new hig.
Now that more than half of 2022 has passed, the data shows that, according to a rough estimate of the drug name, the NMPA has approved a total of 68 generic drugs (92 specifications) to be marketed this year, of which 39 drugs have been approved for the first tim.
Among them, pharmaceutical companies such as Hengrui Pharmaceutical and Kelun Pharmaceutical have become the big winners from the perspective of the first imitation approved companie.
Taking Hengrui Medicine as an example, from 2022 to now, Hengrui Medicine has 1 category 1 new drug approved for the first time, and 1 category 1 new drug with new indications; 9 varieties have been approved for production and are deemed to have been reviewed, including 6 as the first imitatio.
The six first generic drugs are nimodipine oral solution, ondansetron oral dissolving film, acetaminophen mannitol injection, gadobutrol injection, diquafosol sodium eye drops and tacrolimus Sustained release capsule.
It is reported that among the 6 first imitations, nimodipine oral solution, ondansetron oral dissolving film, tacrolimus sustained-release capsule, and acetaminophen mannitol injection are new dosage form.
The data shows that the sales volume of nimodipine, ondansetron, and tacrolimus in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals in 2021 will exceed 70%, respectivel.
100 million yuan, 1 billion yuan, 5 billion yua.
And Kelun Pharmaceuticals (including subsidiaries) has 12 new categories of reported product varieties approved for production since 2022 and deemed to have been reviewe.
Among them, Trolagliptin succinate tablets, medium and long chain fat emulsion/amino acid (16)/glucose (36%) injection, medium and long chain fat emulsion/amino acid (16)/glucose (30%) injection, citric acid Sildenafil acid orally disintegrating tablets and gadoterol injection are the first imitations (including the first imitation of the dosage form), and there are 5 in tota.
In 2021, the market size of sildenafil in China's urban physical pharmacy terminals and China's online pharmacy terminals will exceed 4 billion yua.
According to the data, there are currently 82 varieties of Kelun Pharmaceutical that have passed or are deemed to have passed the consistency evaluation, of which 34 have been evaluated by the first hom.
In addition, Yangzijiang, Beijing Hanmi Pharmaceutical, and China Bio have also had two first generic drugs approved for marketing since the beginning of this yea.
More than 20 pharmaceutical companies including Shandong New Era Pharmaceuticals, Qilu Pharmaceuticals, Jiangsu Hansoh, and Jichuan Pharmaceuticals also successfully obtained the first generic drug.
Among them, the two first generic drugs approved by Yangzijiang Pharmaceutical are Shugeng Sodium Glucose Sodium Injection and Tedizolid Phosphate for Injectio.
According to the data, tedizolid phosphate is a derivative of linezolid and is a second-generation oxazolidinone antibioti.
The two first generic drugs approved by Beijing Hanmei Pharmaceutical are Amlodipine Losartan Potassium Tablets (II) and Amlodipine Losartan Potassium Tablets (I.
Data show that amlodipine and losartan is a compound antihypertensive drug, suitable for the treatment of essential hypertension, and monotherapy cannot adequately control blood pressur.
The two first generic drugs approved by China Biotechnology are sitagliptin and metformin sustained-release tablets and methacholine for inhalatio.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.